.jpg?downsize=390:292 "Stock Market Today: Sensex Slumps Over 1,000 Points At Close, Nifty Declines 1.4%")
As 3:26 p.m., the Dow Jones Industrial Average futures and S&P 500 futrues were down 0.31% and 0.25%, respectively. The Nasdaq 100 futures was 0.07% down.
US: Core Retail Sales
US: Retail Sales
US: Capacity Utilization Rate
US: Industrial Production
US: Business Inventories
US: NAHB Housing Market Index
Nifty and Sensex fell for a second consecutive session losing 2% this week
Intraday, both Nifty and Sensex had declined 1.4% each
Nifty ends 1.35% or 332.25 points down at 24336
Sensex ends 1.3% or 1,064.12 points lower at 80684.45
Broader indices outperformed. Both Nifty Midcap 100 and Nifty Smallcap 250 closed 0.6% lower
Except Nifty Media, which closed flat, all sectoral indices fell
Cipla was the only stock that gained among Nifty constituents
Shriram Finance and Grasim Industries fell the most
Rupee weakened by 3 paise to end at a record closing low of 84.90 against the US Dollar. The currency weakened to 84.93 during the day. It closed at 84.87 on Monday.
Source: Bloomberg
Nazara Technologies' paper boats apps is in pact with Moonbug Entertainment to expand Kiddopia's Content, an exchange filing said.
At 2:15 p.m., Euro Stoxx 50 was 0.3% down, UK's FTSE 100 fell 0.8%, Germany's DAX traded 0.2% down, France CAC 40 fell 0.4%, and Spain's Ibex 35 traded 0.5% down. Markets around the world await US Federal Reserve's rate cut decision due tomorrow night along with UK's central bank decision due Thursday.
South Korea's Kospi ended more than 1% down, Japan's Nikkei fell 0.2%, and Hong Kong's Hang Seng was 0.7% down at close.
Khaitan Chemicals rose the most by 9%, followed by National Fertilizers rising and Rastriya Chemical and Fertilisers 5%, NACL and FACT which traded 3% higher.
Paytm Share Price Rallies For Third Consecutive Day, Remains Above Rs 1,000-Mark
Trading Ideas: Hold Mastek, PG Electroplast, Tata Motors For Long Term
RMC Switchgears has received an order worth Rs 90 crore for 5,000 solar pumps in Maharashtra, an exchange filing said.
FTSE Rejig: Bharti Hexacom, Go Digit General Insurance Join Ranks
Analysts have ‘buy’ calls on Glenmark Pharmaceuticals Ltd., Hyundai Motor India Ltd., GE Vernova T&D India Ltd., Schneider Electric Infrastructure Ltd. and Prestige Estates Projects Ltd. The stock calls came from Shrikant Chouhan, executive vice president and head equity research, Kotak Securities Ltd., Milan Vaishnav, CMT, MSTA, founder and technical analyst, Gemstone Equity Research and Sneha S
Read here.
India's food delivery aggregator Zomato Ltd. is set to bring in an inflow of $513 million or approximately Rs 4,356 crore, as it gears up to replace JSW Steel Ltd. in the upcoming December Sensex rejig, according to Nuvama Alternative & Quantitative Research.
Read more here.
Piramal Pharma share price rose nearly 5% on Tuesday after JM Financial initiated coverage on the stock with a 'buy' rating, and a target price of Rs 340, implying a 36% potential upside.
The stock is currently trading at a 38% discount to its listed peers, making it an attractive opportunity for investors, holds the brokerage.
Rupee Opens At A Record Low After A Record Trade Deficit
At pre-open, Nifty 50 was at 24584.80, down 0.34% or 83.45 points and Sensex was at 81514.75, down by 0.29% or 233.82 points.
The yield on the 10-year bond opened flat at 6.74%.
It closed at 6.74% on Monday.
Source: Bloomberg
Rupee weakened by 3 paise to a record low of 84.9 against the US Dollar. It closed at 84.87 on Monday.
Source: Bloomberg
Citi has maintained 'buy' with a target price of Rs 485, implying downside of 5.6%. Board Announces 4th Interim Dividend of Rs 8.5/share, record date 24th December.
Carraro India has set price band at Rs 668-704/share and bid for issue will open on December 20 and close on December 24, a company statement said.
JM Financial has initiated coverage on Piramal Pharma with a buy rating and a target of Rs 340, implying 36% upside. India’s CRDMO market is expected to double by 2028, boosting opportunities and Piramal Pharma’s global capabilities position it to capitalize on growth. CDMO segment is expected to grow at 17% CAGR over 3 years and recovery in US biotech from 2HFY25 will support growth. The company's overall revenue projected to grow at 15% CAGR over FY24-27 and margins to expand by 360 bps to 18%.
Most markets in Asia–Pacific markets were trading higher ahead of the Federal Reserve policy outcome. South Korea's Kospi traded in red as political uncertainties in the nation continue to weigh on investors' sentiments.
On Monday, the Dow Jones Industrial Average ended 0.25% down. The S&P 500 and Nasdaq Composite ended 0.38% and 1.24% higher, respectively.